chain, SLAMF7, NKG2D, and GPRC5D have been identified as effective targets for CAR T-cell therapy (Fig.3). BCMA, a protein present in high concentrations on a small subset of healthy blood cells and multiple myeloma cells, is the most extensively studied CAR target for myeloma. BCMA, a...